The objective of this work is to document performance of automated insulin delivery (AID) during real-life use in type 2 diabetes (T2D).
Methods:
A retrospective analysis was performed of continuous glucose monitoring and insulin delivery data from 796 individuals with T2D, who transitioned from 1-month predictive low-glucose suspend (PLGS) use to 3-month AID use, in real-life settings. Primary outcome was change of time in range (TIR = 70-180 mg/dL) from PLGS to AID. Secondary outcomes included time above/below range (TAR/TBR) and total daily insulin (TDI).
Results:
Compared with PLGS, AID increased TIR on average from 63.2% to 72.6%, decreased TAR from 36.2% to 26.8%, and increased TDI from 70.2 to 76.3 U (all P < .001), without significant change to TBR. Glycemic improvements were more pronounced in those with worse glycemic control during PLGS use (P < .001).
Conclusions:
Real-life use of AID led to a rapid and sustained improvement of glycemic control in individuals with T2D.
American Diabetes Association. Diagnosis and classification of diabetes: standards of care in diabetes–2024. Diabetes Care. 2024;47:S20-S42.
2.
American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of care in diabetes–2024. Diabetes Care. 2024;47:S158-S178.
3.
ThabitHTauschmannMAllenJM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. 2015;373:2129-2140.
4.
BergenstalRMGargSWeinzimerSA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316:1407-1408.
5.
BrownSAKovatchevBPRaghinaruD, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381:1707-1717.
6.
BrownSAForlenzaGPBodeBW, et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021;44(7):1630-1640.
7.
Bionic Pancreas Research Group. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med. 2022;387:1161-1172.
8.
KovatchevBPSinghHMuellerLGonder-FrederickLA. Biobehavioral changes following transition to automated insulin delivery: a large real-life database analysis. Diabetes Care. 2022;45:2636-2643.
9.
KumareswaranKThabitHLeelarathnaL, et al. Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomized controlled study. Diabetes Care. 2014;37(5):1198-1203.
10.
ThabitHHartnellSAllenJMGonder-FrederickLA. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol. 2017;5(2):117-124.
11.
BallyLThabitHHartnellS, et al. Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med. 2018;379:547-556.
12.
TalebNCarpentierACMessierVLadouceurMHaidarARabasa-LhoretR. Efficacy of artificial pancreas use in patients with type 2 diabetes using intensive insulin therapy: a randomized crossover pilot trial. Diabetes Care. 2019;42(7):e107-e109.
13.
BoughtonCKBallyLMartignoniF, et al. Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomized controlled trial. Lancet Diabetes Endocrinol. 2019;7:368-377.
14.
BoughtonCKTripylaAHartnellS, et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med. 2021;27:1471-1476.
15.
HerzigDSuhnerSRoosJ, et al. Perioperative fully closed-loop insulin delivery in patients undergoing elective surgery: an open-label, randomized controlled trial. Diabetes Care. 2022;45:2076-2083.
16.
DalyABBoughtonCKNwokoloM, et al. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. Nat Med. 2023;29(1):203-208.
17.
LevyCJRaghinaruDKudvaYC, et al. Beneficial effects of Control-IQ automated insulin delivery in basal-bolus and basal-only insulin users with type 2 diabetes. Clin Diabetes. 2024;42(1):116-124.
18.
BauzaCKanapkaLGGreeneELalRAArbiterBBeckRW. Use of the community-derived open-source automated insulin delivery Loop system in type 2 diabetes. Diabetes Technol Ther. 2024;26(7):494-497.
19.
AmerBEYaqoutYEAbozaidAMAfifiEAboelkhierMM. Does fully closed-loop automated insulin delivery improve glycaemic control in patients with type 2 diabetes? A meta-analysis of randomized controlled trials. Diabet Med. 2024;41(1):e15196.
20.
BattelinoTDanneTBergenstalRM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603.
21.
BergenstalRMBeckRWCloseKL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41:2275-2280.
22.
American Diabetes Association. Glycemic goals and hypoglycemia: standards of care in diabetes–2024. Diabetes Care. 2024;47:S111-S125.
